Pre- and post-treatment evaluation of non-Hodgkin's lymphoma

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 429-447

  Mavromatis, Blanche H ^a   Cheson, Bruce D ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gallium scan; Lymphoma; PET scan; Response assessment; Staging

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM; METHOTREXATE; PLATINUM DERIVATIVE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ANAMNESIS; BILE DUCT OBSTRUCTION; BLOOD CHEMISTRY; CANCER RECURRENCE; CAVA VEIN OBSTRUCTION; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; FOLLOW UP; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PATIENT CARE; PATIENT MONITORING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD COMPRESSION; STANDARDIZATION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; URETER OBSTRUCTION; BLOOD CELL COUNT; BONE MARROW EXAMINATION; BREAST CANCER; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PRACTICE; CLINICAL RESEARCH; ENDOSCOPY; EYE CANCER; IMAGING; LABORATORY TEST; LUMBAR PUNCTURE; LYMPH NODE; LYMPHOMA; REMISSION; SEROLOGY; SPLEEN EXAMINATION; STOMACH LYMPHOMA; SYSTEMIC THERAPY; TESTIS CANCER; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DIAGNOSTIC IMAGING; METHODOLOGY; OUTCOME ASSESSMENT; PATHOLOGY;

DIAGNOSTIC IMAGING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS;

EID: 0036455075     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0217     Document Type: Article

References (64)

1. Dorfman RE, Alpern MB, Gross BH & Sandler MA.. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991; 180: 319-322.
2. Einstein DM, Singer AA, Chilcote WA & Desai RK. Abdominal lymphadenopathy: spectrum of CT findings. RadioGraphics 1991; 11: 457-472.
3. Glazer GM, Gross BH, Quint LE et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. American Journal of Radiology 1985; 144: 261-265.
4. Hopper KD, Kasales CJ, van Slyke MA et al. Analysis of interobserver and intraobserver variability in CT tumour measurements. American Journal of Radiology 1996; 187: 851-854.
5. Kiyono K, Sone S, Sakai F et al. The number and size of normal mediastinal lymph nodes: a postmortem study. American Journal of Radiology 1988; 150: 771-776.
6. Steinkamp HJ, Hosten N, Richter C et al. Enlarged cervical lymph nodes at helical CT. Radiology 1994; 191: 795-798.
7. van den Brekel MWM, Castelijns JA & Snow GB. Detection of lymph node metastases in the neck: radiologic criteria. Radiology 1994; 192: 617-617.
8. Genereux GP & Howie JL. Normal mediastinal lymph node size and number: CT and anatomic study. American Journal of Radiology 1984; 142: 1095-1100.
9. Strijk SP, Boetes C, Bogman MJJT et al. The spleen in non-Hodgkin lymphoma. Diagnostic value of computed tomography. Acto Radiologica 1987; 28(Fasc 2): 139-144.
10. Breiman RS, Beck JW, Korobkin M et al. Volume determinations using computed tomography. American Journal of Radiology 1982; 138: 329-333.
11. Shipp MA, Harrington DP, Anderson JR et al. Development of a predictive model for aggressive lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine 1993; 329: 987-994.
12. Cheson BD, Schumann JJ & Schumann GB. Urinary cytodiagnostic examination in 50 patients with non-Hodgkin's lymphomas. Cancer 1984; 54: 1914-1919.
13. Coller BS, Chabner BA & Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin's lymphomas: observations on the value of bilateral biopsies. American Journal of Hematology 1977; 3: 105-119.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology 1999; 17: 1244-1253.
15. Palacio C, Acebedo G, Navarrete M et al. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas, Haematologica 2001; 86: 934-940.
16. Hanson CA, Kurtin PJ, Katzmann JA et al. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell lymphomas. Blood 1999; 94: 3889-3996.
17. Hoane BR, Shields AF, Porter BA & Shulman HM. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 1991; 78: 728-738.
18. Altehoefer C, Blum U, Bathmann J et al. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintography for detection of bone marrow involvement in patients with malignant lymphoma. Journal of Clinical Oncology 1997; 15: 1754-1760.
19. Moog F, Bangerter M, Kotzerke J et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 1998; 16: 603-609.
20. Carr R, Barrington SF, Madan B et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-3346.
21. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Annals of Oncology 1995; 6: 257-262.
22. Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
23. Hiddemann W, Unterhalt M, Hermann R et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with' follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. Journal of Clinical Oncology 1998; 16: 1922-1930.
24. Savio A, Franzin G, Wotherspoon AC et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: Histology, polymerase chain reaction, or both? Blood 1996; 87: 1255-1260.
25. Devizzi L, Maffiolo L, Bonfante V et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Annals of Oncology 1997; 8 (supplement 1): 53-56.
26. Longo DL, Schilsky RL, Blei L et al. Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. American Journal of Medicine 1980; 68: 695-700.
27. Hill M, Cunningham D, MacVicar D et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. Journal of Clinical Oncology 1993; 11: 2273-2278.
28. Israel O, Front D, Lam M et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 2439-2443.
29. Kaplan WD, Jochelson MS, Herman TS et al, Gallium-67 imaging: a predictor of residual tumour viability and clinical outcome in patients with diffuse large-cell lymphoma. Journal of Clinical Oncology 1990; 8: 1966-1970.
30. Janicek M, Kaplan W, Neuberg D et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. Journal of Clinical Oncology 1997; I5: 1631-1637.
31. Even-Sapir E, Bar-Shalom R, Israel O et al. Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. Journal of Clinical Oncology 1995; 13: 942-946.
32. Vose JM, Bierman PJ, Anderson JR et al. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology 1996; 14: 2473-2479.
33. Najjar F, Hustinx R, Jerusalem G et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biotherapy and Radiopharmaceuticals 2001; 16. 297-304.
34. Hoffmann M, Kletter K, Diemling M et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Annals of Oncology 1999; 10: 1185-1189.
35. Römer W, Hahauske A-R, Zieger S et al. Positron-emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
36. Buchmann I, Reinhardt M, Elsner K et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889-899.
37. Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Annals of Oncology 1999; 10: 1141-1143.
38. Löpez-Guillermo A, Montserrat E, Bosch F et al. Applicability of the International Prognostic Index for aggressive lymphomas in patients with low-grade lymphoma. Journal of Clinical Oncology 1994; 12: 1343-1348.
39. Hermans J, Krol ADG, van Groningen K et al. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-1463.
40. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. Journal of Clinical Oncology 1989; 7: 1630-1636.
41. Grillo-López AJ, McLaughlin P, Cheson BD et al. Final report on the application of the new response criteria (RC) proposed for NHL: the rituximab pivotal trial. Proceedings of the American Society of Clinical Oncology 1999; 17: 13a (abstract 44).
42. Grillo-López AJ, Cheson B, Horning S et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Annals of Oncology 1998; 11: 399-408.
43. Lewis E, Bernardino ME, Salvador PG et al. Post-therapy CT-detected mass in lymphoma patients: is it viable tissue? Journal of Computer Assisted Tomography 1982; 6: 792-795.
44. Fuks JZ, Aisner J & Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin lymphomas. Medical and Pediatric Oncology 1982; 10: 429-438.
45. Stewart FM, Williamson BR, Innes; DJ & Hess CE. Residual tumour masses following treatment for advanced histiocytic lymphoma. Cancer 1985; 55: 620-623.
46. Surbone A, Longo DL, DeVita Jr VT et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal of Clinical Oncology 1988; 6: 1832-1837.
47. Longo DL, DeVita VT Jr, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. Journal of Clinical Oncology 1991; 9: 25-38.
48. Waits TM, Greco FA, Greer JP et al. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. Journal of Clinical Oncology 1993; 11: 943-949.
49. Meyer RM, Quirt IC, Skillings JR et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 1770-1776.
50. Zuckerman KS, LoBuglio AF & Reeves JA. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen. Journal of Clinical Oncology 1990; 8: 248-256.
51. Zuckerman KS, Case Jr DC, Gams RA & Prasthofer EF. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen. Blood 1993; 82: 3564-3573.
52. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. Journal of Clinical Oncology 1989; 7: 1018-1026.
53. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. Journal of Clinical Oncology 1992; 10: 1690-1695.
54. Weeks JC, Yeap BY, Canellos GP & Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. Journal of Clinical Oncology 1991; 9: 1196-1203.
55. Oh YK, Ha CS, Samuels BI et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999; 210: 483-486.
56. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
57. Whitcup SM, de Smet MD, Rubin BI et al. Intraocular lymphoma: clinical and histopathologic diagnosis. Opthalmology 1993; 100: 1399-1406.
58. Ferreri AJ Reni M, Zoldan MC et al. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77: 827-833.
59. O'Neill BP, Dinapoli RP, Kurtin PJ & Habermann TM. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? Journal of Neurooncology 1995; 25: 67-71.
60. Crelin AM, Hudson BV, Bennett MH et al. Non-Hodgkin's lymphoma of the testis. Radiotherapy Oncology 1993; 27: 99-106.
61. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR & Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1993; 338: 1175-1176.
62. Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. New England Journal of Medicine 1994; 330: 1267-1271.
63. Roggero E, Zucca E, Pinotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Annals of Internal Medicine 1995; 122: 767-769.
64. Ribrag V, Bibeau F, El Weshi A et al. Primary breast lymphoma: a report of 20 cases. British Journal of Haematology 2001; 115: 253-256.